Merck Sharp & Dohme LLC and Otsuka Pharmaceutical Co. Ltd. have patented cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the treatment of cancer.

Who is Merck Sharp & Dohme Corp.? Merck Sharp & Dohme Corp. has an estimated net worth of $1.18 Billion. This is based on reported shares across multiple companies, which include OPGEN INC ...

As per the High Court's Order, "Glenmark has been restrained by a decree of permanent injunction from making, using, selling, distributing, advertising, exporting, offering for sale or dealing in ...

The leading Advanced Renal Cell Carcinoma Companies such as Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune, Infinity Pharmaceuticals, NiKang Therapeutics ...

In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against the other best major stocks ...

Case brought by a Tipperary farmer against Merck Sharp and Dohme Chemicals (MSD) is dismissed by the High Court. Report shows the Hanrahan family arriving at court. Shots of Hanrahan farm.

Merck, Sharp and Dohme offer a number of industrial placements for undergraduates looking to gain experience of working in the pharmaceutical industry. Even if work placements are not integrated into ...

The rise in research and development activities in schizophrenia treatment is driving market growth by fostering the development of innovative therapies, including novel antipsychotics and ...